Short Interest in Sensus Healthcare, Inc. (NASDAQ:SRTS) Rises By 14.0%

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,550,000 shares, an increase of 14.0% from the January 15th total of 1,360,000 shares. Based on an average trading volume of 336,000 shares, the days-to-cover ratio is presently 4.6 days. Currently, 11.8% of the company’s shares are sold short.

Sensus Healthcare Stock Performance

NASDAQ SRTS opened at $5.51 on Friday. Sensus Healthcare has a fifty-two week low of $2.91 and a fifty-two week high of $9.33. The stock has a 50 day simple moving average of $7.09 and a two-hundred day simple moving average of $6.86. The stock has a market cap of $90.31 million, a P/E ratio of 13.78 and a beta of 1.24.

Sensus Healthcare (NASDAQ:SRTS) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. Sell-side analysts predict that Sensus Healthcare will post 0.71 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Lake Street Capital assumed coverage on Sensus Healthcare in a research report on Friday, January 31st. They set a “buy” rating and a $18.00 price target on the stock. Maxim Group raised their price target on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, HC Wainwright increased their price objective on Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, February 10th.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new stake in shares of Sensus Healthcare during the fourth quarter valued at approximately $27,000. Barclays PLC bought a new stake in shares of Sensus Healthcare during the fourth quarter valued at approximately $35,000. Truvestments Capital LLC bought a new stake in shares of Sensus Healthcare during the third quarter valued at approximately $32,000. IFP Advisors Inc bought a new stake in shares of Sensus Healthcare during the fourth quarter valued at approximately $95,000. Finally, NewEdge Advisors LLC bought a new stake in shares of Sensus Healthcare during the fourth quarter valued at approximately $109,000. 25.30% of the stock is currently owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.